CELL INTELLIGENCE · 肿瘤细胞治疗研究

靶向 CD19 CAR-T 细胞治疗的非 ICANS 神经毒性与运动及神经认知治疗中出现的不良事件：一例病例报告

Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case

CAR 与嵌合共刺激受体联用增强 T 细胞对低抗原密度的敏感性并促进持久性

Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.

肾脏病学趋势：从虚无主义到抗体介导排斥反应的靶向治疗

Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection.

儿童急性淋巴细胞白血病的新型治疗方法

Novel Therapeutic Approaches in Pediatric Acute Lymphoblastic Leukemia.

淋巴结中 CD38(hi)CD19(dim) 细胞预测接受辅助 PD-1 阻断治疗的 III 期黑色素瘤患者预后良好

CD38(hi)CD19(dim) cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade.

RLN 中 CD8+ TRM 和浆母细胞样 CD38 hi CD19 dim 细胞的基线浸润与接受αPD-1 治疗患者的远处无转移生存期延长强烈相关，支持其作为 III 期黑色素瘤预后生物标志物的潜力。

解析 MYC 介导的对传统抗体与 T 细胞重定向治疗性抗体的逃逸机制

Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies.

新型 NKG2D 靶向双特异性抗体增强 NK 细胞和 T 细胞对恶性 B 细胞的抗体介导杀伤

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.

免疫治疗在成人急性白血病治疗中处于何种地位？

Where do immunotherapies stand in management of acute leukemia in adults?

CAR-T 细胞治疗急性髓系白血病：目前所处的位置

CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?

表征骨髓瘤患者单次运动如何影响血液中克隆性浆细胞与免疫效应细胞频率及体外达雷妥尤单抗疗效

Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratu